Randomized Phase II Trial of Combination Chemotherapy With Panitumumab or Bevacizumab for Patients With Inoperable Cholangiocarcinoma Without KRAS Mutations

Trial Profile

Randomized Phase II Trial of Combination Chemotherapy With Panitumumab or Bevacizumab for Patients With Inoperable Cholangiocarcinoma Without KRAS Mutations

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Panitumumab (Primary) ; Capecitabine; Gemcitabine; Oxaliplatin
  • Indications Cholangiocarcinoma
  • Focus Therapeutic Use
  • Acronyms GOC-B-P
  • Most Recent Events

    • 14 May 2016 Status changed from recruiting to completed.
    • 07 Apr 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 07 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 May 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top